PlateletsPub Date : 2023-12-01Epub Date: 2023-12-05DOI: 10.1080/09537104.2023.2285446
Mila Kovacevic, Graziella Pompei, Vijay Kunadian
{"title":"Tailoring antiplatelet therapy in older patients with coronary artery disease.","authors":"Mila Kovacevic, Graziella Pompei, Vijay Kunadian","doi":"10.1080/09537104.2023.2285446","DOIUrl":"10.1080/09537104.2023.2285446","url":null,"abstract":"<p><p>The older population represents a unique subset of patients due to a higher rate of comorbidities and risk factors, which can lead to a higher rate of ischemic and bleeding events. As a result, older adults are mainly underrepresented or excluded from randomized trials. Although the advancement in the percutaneous coronary intervention field with the development of new technologies, techniques, and potent antiplatelet therapy led to a reduction of ischemic risk, there is still a concern regarding bleeding hazards. Apart from the global utilization of less invasive trans-radial approach and proton pump inhibitors to reduce bleeding risk, proper tailoring of antiplatelet therapy in the older person is imperative. So far, several antiplatelet drugs have been introduced in different clinical scenarios, with dual antiplatelet therapy (combination of acetylsalicylic acid and P2Y<sub>12</sub> inhibitor) recommended after percutaneous coronary intervention. The decision on the choice of antiplatelet drug and the DAPT duration is challenging and should be based on the relationship between ischemia and bleeding with the purpose of reducing ischemic events but not at the expense of increased bleeding complications. This is particularly important in the older population, where the evidence is obscure. The main objective of this review is to summarize the available evidence on contemporary antiplatelet therapy and different approaches of de-escalation strategies in older patients after percutaneous coronary intervention.</p>","PeriodicalId":20268,"journal":{"name":"Platelets","volume":"34 1","pages":"2285446"},"PeriodicalIF":3.3,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138482808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
PlateletsPub Date : 2023-12-01Epub Date: 2022-11-14DOI: 10.1080/09537104.2022.2139821
Talia Falcão Dalçóquio, Mayara Alves Dos Santos, Leandro Silva Alves, Flávia Bittar Brito Arantes, Larissa Ferreira-Santos, Maria Urbana Pinto Brandão Rondon, Remo Holanda M Furtado, Aline Gehlen Ferrari, Paulo Roberto Genestreti Rizzo, Rocio Salsoso, Andre Franci, Luciano Moreira Baracioli, Maria Janieire de Nazare Nunes Alves, Carlos Eduardo Negrão, José Carlos Nicolau
{"title":"Effects of exercise on platelet reactivity after myocardial infarction: a randomized clinical trial.","authors":"Talia Falcão Dalçóquio, Mayara Alves Dos Santos, Leandro Silva Alves, Flávia Bittar Brito Arantes, Larissa Ferreira-Santos, Maria Urbana Pinto Brandão Rondon, Remo Holanda M Furtado, Aline Gehlen Ferrari, Paulo Roberto Genestreti Rizzo, Rocio Salsoso, Andre Franci, Luciano Moreira Baracioli, Maria Janieire de Nazare Nunes Alves, Carlos Eduardo Negrão, José Carlos Nicolau","doi":"10.1080/09537104.2022.2139821","DOIUrl":"10.1080/09537104.2022.2139821","url":null,"abstract":"<p><p>Exercise training (ET) can lower platelet reactivity in patients with cardiovascular risk factors. However, the effects of ET on platelet reactivity in higher-risk patients is unknown. The aim of this study was to evaluate the effects of ET on platelet reactivity in patients with recent myocardial infarction (MI). Ninety patients were randomly assigned 1 month post-MI to the intervention (patients submitted to a supervised ET program) or control group. All patients were on dual antiplatelet therapy (DAPT). Platelet reactivity by VerifyNow-P2Y<sub>12</sub> (measured by P2Y<sub>12</sub> reaction units - PRUs) test was determined at baseline and at the end of 14 ± 2 weeks of follow-up at rest (primary endpoint), and multiplate electrode aggregometry (MEA) adenosine diphosphate (ADP) and aspirin (ASPI) tests were performed immediately before and after the maximal cardiopulmonary exercise test (CPET) at the same time points (secondary endpoints). Sixty-five patients (mean age 58.9 ± 10 years; 73.8% men; 60% ST elevation MI) completed follow-up (control group, n = 31; intervention group, n = 34). At the end of the follow-up, the mean platelet reactivity was 172.8 ± 68.9 PRUs and 166.9 ± 65.1 PRUs for the control and intervention groups, respectively (p = .72). Platelet reactivity was significantly increased after the CPET compared to rest at the beginning and at the end of the 14-week follow-up (among the intervention groups) by the MEA-ADP and MEA-ASPI tests (p < .01 for all analyses). In post-MI patients on DAPT, 14 weeks of supervised ET did not reduce platelet reactivity. Moreover, platelet reactivity was increased after high-intensity exercise (ClinicalTrials.gov: NCT02958657; https://clinicaltrials.gov/ct2/show/NCT02958657).</p>","PeriodicalId":20268,"journal":{"name":"Platelets","volume":" ","pages":"2139821"},"PeriodicalIF":3.3,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40474991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
PlateletsPub Date : 2023-12-01Epub Date: 2022-11-02DOI: 10.1080/09537104.2022.2136646
Tahsin Özpolat, Olga Yakovenko, Anastasiia Stratiievska, S Lawrence Bailey, Jeffrey Miles, Chomkan Usaneerungrueng, Daire Byrne, Xiaoping Wu, Moritz Stolla
{"title":"Evaluating stored platelet shape change using imaging flow cytometry.","authors":"Tahsin Özpolat, Olga Yakovenko, Anastasiia Stratiievska, S Lawrence Bailey, Jeffrey Miles, Chomkan Usaneerungrueng, Daire Byrne, Xiaoping Wu, Moritz Stolla","doi":"10.1080/09537104.2022.2136646","DOIUrl":"10.1080/09537104.2022.2136646","url":null,"abstract":"<p><p>Platelets are routinely stored at room temperature for 5-7 days before transfusion. Stored platelet quality is traditionally assessed by Kunicki's morphology score. This method requires extensive training, experience, and is highly subjective. Moreover, the number of laboratories familiar with this technique is decreasing. Cold storage of platelets has recently regained interest because of potential advantages such as reduced bacterial growth and preserved function. However, platelets exposed to cold temperatures change uniformly from a discoid to a spherical shape, reducing the morphology score outcomes to spheroid versus discoid during cooling. We developed a simpler, unbiased screening tool to measure temperature-induced platelet shape change using imaging flow cytometry. When reduced to two dimensions, spheres appear circular, while discs are detected on a spectrum from fusiform to circular. We defined circular events as having a transverse axis of >0.8 of the longitudinal axis and fusiform events ≤0.8 of the longitudinal axis. Using this assay, mouse and human platelets show a temperature and time-dependent, two-dimensional shape change from fusiform to circular, consistent with their three-dimensional change from discs to spheres. The method we describe here is a valuable tool for detecting shape change differences in response to agonists or temperature and will help screening for therapeutic measures to mitigate the cold-induced storage lesion.</p>","PeriodicalId":20268,"journal":{"name":"Platelets","volume":"34 1","pages":"2136646"},"PeriodicalIF":2.5,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9833271/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10515944","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
PlateletsPub Date : 2023-12-01Epub Date: 2023-02-21DOI: 10.1080/09537104.2023.2170999
Adele Barlassina, Tomás José González-López, Nichola Cooper, Francesco Zaja
{"title":"European Delphi panel to build consensus on tapering and discontinuing thrombopoietin receptor agonists in immune thrombocytopenia.","authors":"Adele Barlassina, Tomás José González-López, Nichola Cooper, Francesco Zaja","doi":"10.1080/09537104.2023.2170999","DOIUrl":"10.1080/09537104.2023.2170999","url":null,"abstract":"<p><p>To establish pan-European consensus on tapering and discontinuing thrombopoietin receptor agonists (TPO-RAs) in patients with immune thrombocytopenia (ITP), we applied a three-step Delphi technique consisting of a one-to-one interview round and two online survey rounds. Three healthcare professionals (HCPs) from Italy, Spain, and the United Kingdom formed the Steering Committee (SC), which advised on study design, panelist selection, and survey development. A literature review also informed the development of the consensus statements. Likert scales were used to collect quantitative data on panelists' level of agreement. Twelve hematologists representing nine European countries assessed 121 statements spanning three categories: (1) patient selection; (2) tapering and discontinuation strategies; (3) post-discontinuation management. Consensus was reached on approximately half of the statements in each category (32.2%; 44.6%; 66%). Panelists agreed on patients' main selection criteria, patients' involvement in decision-making, tapering strategies, and follow-up criteria. Areas not reaching consensus were risk factors and predictors of successful discontinuation, monitoring intervals, and rates of successful discontinuation or relapse. This lack of consensus signals knowledge and practice gaps among European countries and suggests the need for the development of clinical practice guidelines that outline a pan-European, evidence-based approach to tapering and discontinuing TPO-RAs.</p>","PeriodicalId":20268,"journal":{"name":"Platelets","volume":" ","pages":"2170999"},"PeriodicalIF":3.3,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9348671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
PlateletsPub Date : 2023-12-01DOI: 10.1080/09537104.2023.2217932
Joseph E Aslan
{"title":"How can we use proteomics to learn more about platelets?","authors":"Joseph E Aslan","doi":"10.1080/09537104.2023.2217932","DOIUrl":"10.1080/09537104.2023.2217932","url":null,"abstract":"<p><p>Proteomics tools provide a powerful means to identify, detect, and quantify protein-related details in studies of platelet phenotype and function. Here, we consider how historical and recent advances in proteomics approaches have informed our understanding of platelet biology, and, how proteomics tools can be used going forward to advance studies of platelets. It is now apparent that the platelet proteome is comprised of thousands of different proteins, where specific changes in platelet protein systems can accompany alterations in platelet function in health and disease. Going forward, many challenges remain in how to best carry out, validate and interpret platelet proteomics experiments. Future studies of platelet protein post-translational modifications such as glycosylation, or studies that take advantage of single cell proteomics and top-down proteomics methods all represent areas of interest to profiling and more richly understanding platelets in human wellness and disease.</p>","PeriodicalId":20268,"journal":{"name":"Platelets","volume":"34 1","pages":"2217932"},"PeriodicalIF":2.5,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11524195/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9907532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
PlateletsPub Date : 2022-12-01DOI: 10.1080/09537104.2022.2151996
Soomin Kim, Yujin Kim, Shin-Hye Yu, Seo-Eun Lee, Jong Hyeok Park, Gayoung Cho, Chul Choi, Kyuboem Han, Chun-Hyung Kim, Young Cheol Kang
{"title":"Platelet-derived mitochondria transfer facilitates wound-closure by modulating ROS levels in dermal fibroblasts.","authors":"Soomin Kim, Yujin Kim, Shin-Hye Yu, Seo-Eun Lee, Jong Hyeok Park, Gayoung Cho, Chul Choi, Kyuboem Han, Chun-Hyung Kim, Young Cheol Kang","doi":"10.1080/09537104.2022.2151996","DOIUrl":"https://doi.org/10.1080/09537104.2022.2151996","url":null,"abstract":"<p><p>Platelets are known to improve the wound-repair capacity of mesenchymal stem cells (MSCs) by transferring mitochondria intercellularly. This study aimed to investigate whether direct transfer of mitochondria (pl-MT) isolated from platelets could enhance wound healing <i>in vitro</i> using a cell-based model. Wound repairs were assessed by 2D gap closure experiment in wound scratch assay using human dermal fibroblasts (hDFs). Results demonstrated that pl-MT were successfully internalized into hDFs. It increased cell proliferation and promoted the closure of wound gap. Importantly, pl-MT suppressed both intracellular and mitochondrial ROS production induced by hydrogen peroxide, cisplatin, and TGF-β in hDFs. Taken together, these results suggest that pl-MT transfer might be used as a potential therapeutic strategy for wound repair.</p>","PeriodicalId":20268,"journal":{"name":"Platelets","volume":"34 1","pages":"2151996"},"PeriodicalIF":3.3,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9564190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
PlateletsPub Date : 2022-11-17DOI: 10.1080/09537104.2022.2069235
Hilaire Yam Fung Cheung, Luis A Moran, Albert Sickmann, Johan W M Heemskerk, Ángel Garcia, Steve P Watson
{"title":"Inhibition of Src but not Syk causes weak reversal of GPVI-mediated platelet aggregation measured by light transmission aggregometry.","authors":"Hilaire Yam Fung Cheung, Luis A Moran, Albert Sickmann, Johan W M Heemskerk, Ángel Garcia, Steve P Watson","doi":"10.1080/09537104.2022.2069235","DOIUrl":"https://doi.org/10.1080/09537104.2022.2069235","url":null,"abstract":"<p><p>Src tyrosine kinases and spleen tyrosine kinase (Syk) have recently been shown to contribute to sustained platelet aggregation on collagen under arterial shear. In the present study, we have investigated whether Src and Syk are required for aggregation under minimal shear following activation of glycoprotein VI (GPVI) and have extended this to C-type lectin-like receptor-2 (CLEC-2) which signals through the same pathway. Aggregation was induced by the GPVI ligand collagen-related peptide (CRP) and the CLEC-2 ligand rhodocytin and monitored by light transmission aggregometry (LTA). Aggregation and tyrosine phosphorylation by both receptors were sustained for up to 50 min. The addition of inhibitors of Src, Syk or Bruton's tyrosine kinase (Btk) at 150 sec, by which time aggregation was maximal, induced rapid loss of tyrosine phosphorylation of their downstream proteins, but only Src kinase inhibition caused a weak (~10%) reversal in light transmission. A similar effect was observed when the inhibitors were combined with apyrase and indomethacin or glycoprotein IIb-IIIa (GPIIb-IIIa) antagonist, eptifibatide. On the other hand, activation of GPIIb-IIIa by GPVI in a diluted platelet suspension, as measured by binding of fluorescein isothiocyanate-labeled antibody specific for the activated GPIIb-IIIa (FITC-PAC1), was reversed on the addition of Src and Syk inhibitors showing that integrin activation is rapidly reversible in the absence of outside-in signals. The results demonstrate that Src but not Syk and Btk contribute to sustained aggregation as monitored by LTA, possibly as a result of inhibition of outside-in signaling from GPIIb-IIIa to the cytoskeleton through a Syk-independent pathway. This is in contrast to the role of Syk in supporting sustained aggregation on collagen under arterial shear.</p>","PeriodicalId":20268,"journal":{"name":"Platelets","volume":"33 8","pages":"1293-1300"},"PeriodicalIF":3.3,"publicationDate":"2022-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10841366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
PlateletsPub Date : 2022-11-17DOI: 10.1080/09537104.2022.2107627
Brittney Williams, Jing Zhu, Lin Zou, Wei Chao
{"title":"Innate immune TLR7 signaling mediates platelet activation and platelet-leukocyte aggregate formation in murine bacterial sepsis.","authors":"Brittney Williams, Jing Zhu, Lin Zou, Wei Chao","doi":"10.1080/09537104.2022.2107627","DOIUrl":"https://doi.org/10.1080/09537104.2022.2107627","url":null,"abstract":"<p><p>Thrombocytopenia is a common complication in sepsis and is associated with higher mortality. Activated platelets express CD62P, which facilitates platelet-leukocyte aggregate (PLA) formation and contributes to thrombocytopenia in sepsis. We have reported that thrombocytopenia in murine sepsis is partly attributable to TLR7 signaling, but the underlying mechanism is unclear. In the current study, we tested the hypothesis that TLR7 mediates platelet activation and PLA formation during sepsis. In vitro, whole blood from WT mice treated with loxoribine, a TLR7 agonist, exhibited a dose-dependent increase in activated platelets compared to the control (PBS with 0.05% DMSO) or loxoribine-treated TLR7<sup>-/-</sup> whole blood. In a murine model of sepsis, there was a significant increase in platelet activation and PLA formation 24 hours after cecal ligation and puncture (CLP) as evidenced by double positive expression of CD41<sup>+</sup>/CD62P<sup>+</sup> and CD45<sup>+</sup>/CD62P<sup>+</sup>, respectively. The sepsis-induced PLA formation was significantly attenuated in TLR7<sup>-/-</sup> mice. Finally, in ex-vivo experiments, plasma isolated from septic mice induced WT platelet activation, but such effect was significantly attenuated in platelets deficient of TLR7. These findings demonstrate a pivotal role of TLR7 signaling in platelet activation and PLA formation during bacterial sepsis.</p>","PeriodicalId":20268,"journal":{"name":"Platelets","volume":"33 8","pages":"1251-1259"},"PeriodicalIF":3.3,"publicationDate":"2022-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9833650/pdf/nihms-1860245.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10521674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
PlateletsPub Date : 2022-11-17Epub Date: 2022-06-29DOI: 10.1080/09537104.2022.2087868
Sean P Heffron, Joseph Windheim, Tessa J Barrett, Deepak Voora, Jeffrey S Berger
{"title":"Platelet inhibition by low-dose aspirin is not influenced by body mass or weight.","authors":"Sean P Heffron, Joseph Windheim, Tessa J Barrett, Deepak Voora, Jeffrey S Berger","doi":"10.1080/09537104.2022.2087868","DOIUrl":"10.1080/09537104.2022.2087868","url":null,"abstract":"<p><p>Aspirin's clinical efficacy may be influenced by body weight and mass. Although inadequate platelet inhibition by aspirin is suggested as responsible, evidence for this in non-diabetic patients is sparse. We investigated the influence of body weight and mass on aspirin's inhibition of platelet aggregation in healthy adults without diabetes. Cohort one (NYU, n = 84) had light transmission aggregometry (LTA) of platelet-rich plasma to submaximal adenosine diphosphate (ADP) and arachidonic acid (AA) before and following 1 week of daily 81 mg non-enteric coated aspirin. Subjects in the validation cohort (Duke, n = 66) were randomized to 81 mg or 325 mg non-enteric coated aspirin for 4 weeks, immediately followed by 4 weeks of the other dose, with LTA to submaximal collagen, ADP, and AA before and after each dosage period. Body mass index (BMI) range was 18.0-57.5 kg/m<sup>2</sup> and 25% were obese. Inhibition of platelet aggregation was similar irrespective of BMI, body weight and aspirin dose. There was no correlation between platelet aggregation before or after aspirin with BMI or body weight. Our data demonstrate that aspirin produces potent inhibition of direct and indirect COX1-mediated platelet aggregation in healthy adults without diabetes regardless of body weight or mass - suggesting that other mechanisms explain lower preventive efficacy of low-dose aspirin with increasing body weight/mass.</p>","PeriodicalId":20268,"journal":{"name":"Platelets","volume":"33 8","pages":"1208-1213"},"PeriodicalIF":3.3,"publicationDate":"2022-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9976777/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9359542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}